TBVAC2020 – Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development

TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time applying portfolio management using gating and priority setting criteria to select as early as possible the most promising TB vaccine candidates, and accelerate their development.
The proposed approach and involvement of many internationally leading groups in the TB vaccine and biomarker area in TBVAC2020 fully aligns with the Global TB Vaccine Partnerships.

Details

Status:

  • inactive

Research Focus:

  • Medicine and Health

Project Coordination:

Stichting TuBerculosis Vaccine Initiative
(TBVI)

Other Partners:

Statens Serum Institut , denmark SCIENSANO, belgium Universiteit Gent, Belgium Bangor University, United Kingdom Universität Ulm, Germany Institut Pasteur, France Centre National De La Recherche Scientifique CNRS, France Universidad de Zaragoza, Spain Universite de Geneve, Switzerland Eidgenoessische Technische Hochschule Zuerich, Switzerland University College Dublin, National University Of Ireland, Dublin, Ireland Yonsei University, South Korea Stichting Biomedical Primate Research Center, Netherlands Department of Health, United Kingdom Universität Zürich, Switzerland Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol, Spain United Kingdom research and Innovation, United Kingdom London School Of Hygiene And Tropical Medicine Royal Charter, United Kingdom Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Di Palermo, Italy Imperial College Of Science Technology And Medicine, United Kingdom Academisch Ziekenhuis Leiden, Netherlands Universite Libre de Bruxelles, Belgium Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Italy The University of Sydnexy, Australia The Chancellor, Masters And Scholars Of The University Of Oxford, United Kingdom The Secretary Of State For Environment, Food And Rural Affairs, United Kingdom Centre Hospitalier Universitaire Vaudois, Switzerland Institut Pasteur De Lille Fondation, France Universite de Lausanne, Switzerland Universitat Basel, Switzerland Istituto Superiore Di Sanita, Italy AERAS GLOBAL TB VACCINE FOUNDATION, United States International Tuberculosis Research Center, South Korea Glaxosmithkline Biologicals SA, Belgium TRANSGENE SA, France Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer Tiergesundheit, Germany University Of Strathclyde, United Kingdom

Countries:

Germany (Bavaria), South Africa

Duration:

01/01/2015
– 30/06/2019

Budget:

18200000 EUR

URL: